The global paradigm shift toward generative artificial intelligence and foundation models has transformed healthcare research, diagnostic radiology, digital pathology and drug discovery. However, this technological frontier has intensified a critical strategic vulnerability for Europe: a profound structural reliance on United States technology conglomerates for computational hardware, cloud infrastructure, and frontier foundation models. While American technology leaders depl

The European healthcare technology (HealthTech) mergers and acquisitions (M&A) landscape has entered a period of structured recalibration. Following post-pandemic market adjustments, current M&A activity reflects a structural transition away from speculative growth toward high-conviction, disciplined transactions. Capital deployment is heavily concentrated in platforms demonstrating clear operational leverage, defensible reimbursement pathways, and deep technological moats.

The global landscape of artificial intelligence governance has crystallised into three distinct philosophical paradigms: the Rights-Based approach championed by the European Union, the Innovation-First model pursued by the Gulf Cooperation Council (GCC) and Singapore, and the State-Directed framework enforced by China. Within this geopolitical matrix, the European Union’s Artificial Intelligence Act (AI Act), which entered into force on August 1st, 2024, serves as the world's